Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep934 | Pituitary - Basic | ECE2017

PP4C restrains dopamine D2 receptor expression in rat pituitary MMQ cells

Yi Na , Lu Bin

Objective: Decline in the number of D2 receptor (D2R) is considered as the reason of resistance to dopamine agonists (DA). PP4R2 gene was observed up-regulated in prolactinoma patients according to our previous genechip study. In this study, we demonstrated that PP4C was crucial for D2R expression and PRL secretion in rat pituitary MMQ cells.Methods: In this study, we used rat pituitary MMQ cells which could secrete abundant prolactin and express functio...

ea0073pep10.6 | Presented ePosters 10: Thyroid | ECE2021

Influence of pro-inflammatory cytokines polymorphisms on the interrelationship between Graves’ disease and diabetes

Celestino Neves , Neves Joao Sergio , Paula Soares , Delgado Luís , Luís Medina Luís , Carvalho Davide

BackgroundGraves’ Disease (GD) is characterized by production of stimulating autoantibodies to thyrotropin receptor resulting in hyperthyroidism. Hyperthyroidism is associated with insulin resistance, hyperglycemia and ketosis. Our aim was to evaluate if single nucleotide polymorphism (SNP) in pro-inflammatory cytokines contributes to dysglycemia in GD.MethodsWe evaluated 98 patients with Graves’ di...

ea0063p516 | Calcium and Bone 2 | ECE2019

Immobilization induced hypercalcemia

Koseoğlu Derya , Helvacı Nafiye

Introduction: Immobilization induced hypercalcemia, which was first described in 1941 by Albright, is an uncommon reason for hypercalcemia. It is associated with increased bone remodeling disorders and conditions associated with limited movement such as medullar lesions or vascular events. The exact mechanism of the disorder is unknown. Diagnosis requires an detailed evaluation to rule out other causes of hypercalcemia.Case presentation: A 24 year old ma...

ea0037ep6 | Adrenal cortex | ECE2015

Clinical and pathological characteristics of hypertensive and normotensive adrenal phaeochromocytomas

Yan Bi , Dalong Zhu , Yao Lu

Context: Distinct differences of clinical manifestations exist in hypertensive pheochromocytomas (HPs) and normotensive phaeochromocytomas (NPs), however the comparative analysis is lacking.Objective: The objective of the study was to assess the clinical symptoms, haemodynamics, metabolism, radiological and histological features of patients with HPs and NPs.Research design and methods: This retrospective study included 104 patients...

ea0070aep76 | Adrenal and Cardiovascular Endocrinology | ECE2020

Bronchogenic cyst mimicking adrenal mass

Köseoğlu Derya

Introduction: Primary retroperitoneal bronchogenic cysts are rarely seen. Bronchogenic cysts are mostly benign which originate from the remnants of the primitive foregut during the embryonic development.These lesions can be seen near or inside any organ that originates from the embryonic foregut. Bronchogenic cysts are most often found in the thoracic cavity, especially in the mediastinum. Except this many distant sites, such as abdomen, retroperitoneum,...

ea0029p897 | Female Reproduction | ICEECE2012

Progesterone levels on the hCG day and outcomes IVF in women with polycystic ovary syndrome

Peng C. , Long X. , Lu G.

Background: The purpose of this study was to determine the incidence of premature luteinization in patients with polycystic ovary syndrome and compared the main determinants of success in IVF in PCOS patients with and without premature luteinization.Methods: Retrospective analysis of 180 PCOS women of Chinese Han origin with infertility who underwent controlled ovarian hyperstimulation (COH) with an exogenous gonadotropin/GnRH antagonist protocol. Hormon...

ea0020p228 | Bone/Calcium | ECE2009

Use of Cinacalcet in patients with intractable primary hyperparathyroidism (PHPT): a UK budget impact analysis

Martin Monique , Robbins Sean , Lu Z John

Introduction: Persistent or intractable PHPT can lead to neuromuscular and psychiatric symptoms and may increase the long-term risk for cardiovascular disease and fractures. Cinacalcet (Mimpara/Sensipar) represents an innovative treatment option for this small group of patients, as it directly acts on the calcium sensing receptors on cell surfaces, reducing the severity of hypercalcemia.Purpose: To estimate the UK budget impact of cinacalcet in patients ...

ea0073aep223 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Free T4 level may be associated with insulin requirement in gestational diabetes mellitus

Ömercan Topaloğlu , Uzun Mehmet

IntroductionGestational diabetes mellitus (GDM) may frequently be overcome by nutrition therapy alone, but insulin regimen may be necessary in about 30 % of the patients with GDM. It was known that thyroid hormones were associated with glucose metabolism. Therefore, we aimed to investigate the association of fT4 level with insulin requirement in euthyroid pregnant women with GDM.Materials and methodsWe consec...

ea0037ep376 | Diabetes (pathiophysiology & epitemiology) | ECE2015

Gonadal hormone regulates the expression MATE1 and OCT2 in type 2 diabetes mice

Ai Ligen , Zhang Dandan , Hou Wolin , Lu Junxi , Tang Junling , Lu Huijuan , Zheng Taishan , Liu Fang

Background and aims: Multi-drug and toxin extrusion 1 (MATE1) and organic cation transporters 2 (OCT2) are important proteins of metformin transport and excretion in liver and kidney. Our previous study showed that there were gender difference of metformin’s hypoglycaemic effect and it was independently linked with the oestrogen and testosterone levels in type 2 diabetes patients. This study was designed to observe the impact of oestrogen and androgen on the renal express...

ea0070ep451 | Thyroid | ECE2020

When levothyroxine is not enough- combination therapy with liothyronine

Veríssimo David , Reis de Almeida Luís , Monteiro Manuel , Dias Luís

Introduction: The treatment of central hypothyroidism with a combination of levothyroxine (T4) and liothyronine (T3) is not recommended for most patients since it does not show an advantage over T4L monotherapy. However, in certain patients who remain symptomatic under replacement therapy with T4L and thyroid stimulating hormone (TSH) within the reference values, combined treatment with T4 and T3 can be tested.Clinical case: Male, 39 years old, medical h...